A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

May 11, 2020

Study Completion Date

October 6, 2021

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Nivolumab

Specified dose on specified day

DRUG

Ipilimumab

Specified Dose on Specified Day

Trial Locations (61)

10016

Local Institution - 0052, New York

10021

Weill Cornell Medical College, New York

10461

Montefiore Medical Center, The Bronx

11220

Maimonides Medical Center, Brooklyn

13210

SUNY Upstate Medical University, Syracuse

13790

Broome Oncology, Johnson City

15240

Local Institution - 0071, Pittsburgh

22031

Local Institution - 0042, Fairfax

22936

University of Virginia Health System, Charlottesville

23114

Bon Secours St Francis Hospital, Midlothian

23226

Virginia Cancer Institute, Richmond

27534

Southeastern Medical Oncology Center, Goldsboro

27710

Duke University Medical Center, Durham

29414

Charleston Hematology Oncology Associates, Pa, Charleston

29425

Hollings Cancer Center, Charleston

30322

Emory University - Winship Cancer Institute, Atlanta

32806

UF Health Cancer Center at Orlando Health, Orlando

33136

University Of Miami/Sylvester Cancer Center, Miami

33705

Florida Cancer Specialists, St. Petersburg

33901

Florida Cancer Specialists S., Fort Myers

35661

Northwest Alabama Cancer Center, Pc, Muscle Shoals

37404

Tennessee Oncology, PLLC - SCRI - PPDS, Chattanooga

39202

Jackson Oncology Associates, Pllc, Jackson

39401

Hattiesburg Clinic, Hattiesburg

40202

Norton Cancer Institute, Louisville

46845

Local Institution - 0012, Fort Wayne

53705

University of Wisconsin Clinical Science Center, Madison

55337

Southdale Cancer Clinic, Burnsville

55416

Park Nicollet Clinic Cancer Center, Minneapolis

55433

Local Institution - 0009, Coon Rapids

57105

Avera Cancer Institute, Sioux Falls

60714

Illinois Cancer Specialists, Niles

64132

HCA Midwest Division, Kansas City

67214

Cancer Center Of Kansas, Wichita

68803

St. Francis Cancer Treatment Center, Grand Island

72703

Local Institution - 0028, Fayetteville

74146

Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research, Tulsa

75246

Texas Oncology, Dallas

76104

Texas Oncology-Fort Worth 12th Ave, Fort Worth

78217

Texas Oncology, San Antonio

78731

Texas Oncology, Austin

79701

Texas Oncology-Midland Allison Cancer Center, Midland

85224

Ironwood Cancer And Research Centers, Pc, Chandler

87106

University Of New Mexico, Albuquerque

89148

Comprehensive Cancer Centers of Nevada, Las Vegas

90017

Los Angeles Cancer Network, Los Angeles

90095

UCLA Hematology Oncology, Los Angeles

90277

Torrance Health Association, Redondo Beach

90813

Pacific Shores Medical Group, Long Beach

92024

eCare, Encinitas

92123

Sharp Memorial Hospital, San Diego

92505

Kaiser Permanente Medical Group - Southern California, Riverside

93401

Coastal Integrative Cancer Care, San Luis Obispo

93454

Central Coast Med Oncology, Santa Maria

98109

University of Washington - Seattle Cancer Care Alliance, Seattle

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

99208

Medical Oncology Associates, Spokane

99503

Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage

07601

Local Institution - 0023, Hackensack

37203-1624

Local Institution - 0002, Nashville

37232-6307

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02982954 - A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | Biotech Hunter | Biotech Hunter